Show simple item record

dc.contributor.authorGrande-Pulido, E.
dc.contributor.authorBolós, María-Victoria
dc.contributor.authorArriola, Edurne
dc.date.accessioned2024-01-24T10:22:12Z
dc.date.available2024-01-24T10:22:12Z
dc.date.issued2011
dc.identifier.issn1538-8514spa
dc.identifier.urihttps://hdl.handle.net/10641/3810
dc.description.abstractRecently, the anaplastic lymphoma kinase (ALK) has been found to be altered in several solid and hematologic tumors. Novel drugs targeting this tyrosine kinase receptor are under development, and early clinical trials are showing promising activity in non-small cell lung cancer patients with ALK+ tumors. Here, we review the structure and function of the ALK receptor, the mechanisms associated with its deregulation in cancer, methods for ALK detection in tumor samples, its potential as a new marker for candidate patient selection for tailored therapy, and novel drugs under development that target ALK.spa
dc.language.isoengspa
dc.publisherMolecular Cancer Therapeuticsspa
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.titleTargeting oncogenic ALK: a promising strategy for cancer treatment.spa
dc.typejournal articlespa
dc.type.hasVersionSMURspa
dc.rights.accessRightsmetadata only accessspa
dc.description.extent935 KBspa
dc.identifier.doi10.1158/1535-7163.MCT-10-0615spa
dc.relation.publisherversionhttps://aacrjournals.org/mct/article/10/4/569/168521/Targeting-Oncogenic-ALK-A-Promising-Strategy-forspa


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 España
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 España